ATXI Avenue Therapeutics Inc.

8.98
-0.21  -2%
Previous Close 9.19
Open 9.19
Price To Book 12.47
Market Cap 149,618,968
Shares 16,661,355
Volume 51,158
Short Ratio
Av. Daily Volume 35,003
Stock charts supplied by TradingView

NewsSee all news

  1. Avenue Therapeutics Announces Submission of New Drug Application for IV Tramadol

    NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, today announced that it has

  2. Avenue Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

    NEW YORK, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, today reported financial results

  3. Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development

    NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, announced today that its Phase 1

  4. Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development

    NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, announced today that its Phase 1

  5. Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development

    NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, announced today that its Phase 1

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

NDA filing announced December 11, 2019.
Intravenous (IV) tramadol
Postoperative pain following bunionectomy surgery

Latest News

  1. Avenue Therapeutics Announces Submission of New Drug Application for IV Tramadol

    NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, today announced that it has

  2. Avenue Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

    NEW YORK, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, today reported financial results

  3. Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development

    NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, announced today that its Phase 1

  4. Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development

    NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, announced today that its Phase 1

  5. Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development

    NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, announced today that its Phase 1

  6. Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development

    NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, announced today that its Phase 1